Clinical trial · Interventional
Phase II Study of Epirubicin, Cisplatin and Capecitabine (ECX) Versus Cisplatin and Capecitabine (CX) for Advanced Gastric Cancer (AGC)
A Randomized Phase II Study of Combination Chemotherapy With Epirubicin , Cisplatin and Capecitabine (ECX) or Cisplatin and Capecitabine (CX) in Advanced Gastric Cancer
NCT00743964CI-TRIAL-00003026completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Recently, 3-drug (ECX) and 2-drug (CX) combination chemotherapy involving capecitabine showed promising results in randomized clinical trials for advanced gastric cancer (AGC). The objective of the study is to evaluate the safety and activity of ECX and CX combination chemotherapy given as first-line therapy for AGC.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Gastric Cancer | Malignant Gastric Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Cisplatin, capecitabine | Drug | — | UNRESOLVED |
| Epirubicin | Drug | Epirubicin | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- ECX
- description
- Epirubicin, cisplatin and capecitabine combination chemotherapy will be administered.
- interventionNames
- Drug: Epirubicin
- Drug: Cisplatin, capecitabine
- type
- ACTIVE_COMPARATOR
- label
- CX
- description
- Cisplatin and capecitabine combination chemotherapy will be administered.
- interventionNames
- Drug: Cisplatin, capecitabine
Primary outcomes (1)
- measure
- Failure-free survival
- timeFrame
- six months
Eligibility
Eligibility (as posted)
- Sex
- All
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Aged 75 years or less * Adenocarcinoma of stomach * Advanced, metastatic, or recurrent * No prio chemotherapy for advanced disease * Adequate performance status * Adequate major organ functions Exclusion Criteria: * Severe comorbid illness or active infections * Pregnancy or lactating women * GI obstruction or malabsorption syndrome
References
Publications (1)
- DERIVEDYun J, Lee J, Park SH, Park JO, Park YS, Lim HY, Kang WK. A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer. Eur J Cancer. 2010 Mar;46(5):885-91. doi: 10.1016/j.ejca.2009.12.015. Epub 2010 Jan 7. PMID 20060288